What ORFLO Technologies does

ORFLO Technologies, operating as Precision Cell Systems, Inc., is a privately-held life sciences instrumentation company founded in 2010 and headquartered in Livermore, California (with a listed address in Ketchum, Idaho). The company develops precision laboratory instruments for upstream cell-based workflows, serving genomics laboratories, translational oncology and cell therapy programs (including CAR-T QC), pharmaceutical and contract research organizations, and flow cytometry core facilities. As of the input, the company has 1,000+ instruments installed globally across 700+ institutions, with 200+ peer-reviewed publications citing its technology, and headcount in the 11-50 band.

The product portfolio centers on two complementary platforms: the Singulator family of automated tissue dissociation systems (Singulator 100, Singulator 200, and Singulator 200+) which convert fresh, frozen, or FFPE tissue into sequencing-ready cells or nuclei via software-locked, cold-temperature (4°C), enzyme-free protocols in 6-10 minutes; and the Moxi family of Coulter-principle impedance-based cell counters (Moxi V, Moxi Z for counting and sizing; Moxi GO II for counting combined with two-color fluorescence). The core technology is Coulter-principle impedance measurement, delivering NIST-traceable volumetric cell counting at <2% coefficient of variation with natural debris exclusion — substantially more precise than image-based alternatives (20-30% CV). The Moxi GO II adds 488nm laser fluorescence with dual PMTs and native 21 CFR Part 11 compliance for regulated environments.

The business model combines capital equipment sales (Singulator and Moxi instruments, quote-based pricing via "Request a Quote" and "Talk to a Specialist"), recurring revenue from disposable cassettes and consumables, and supporting application-scientist consultation services (notably a 20-minute workflow evaluation offering). Go-to-market is sales-led, targeting enterprise buyers through direct sales supported by content marketing, peer-reviewed validation assets, a resource library, webinars (Eventbrite, GenomeWeb, GoToWebinar, Zoom), conference engagement, and an e-commerce store for mid-market consumables access. Total disclosed funding to date is approximately $1.36M across two rounds (2013 and 2017), indicating a capital-efficient, largely revenue-funded operating posture. Compliance footprint includes 21 CFR Part 11 on the Moxi GO II, GDPR, and CCPA.

Name

ORFLO Technologies

Legal name

Precision Cell Systems, Inc.

Website

https://orflo.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

11–50 employees

Short description

ORFLO Technologies (Precision Cell Systems, Inc.) is a privately-held life sciences instrumentation company that develops automated tissue dissociation systems (Singulator) and Coulter-principle cell counters (Moxi) serving genomics labs, cell therapy programs, pharmaceutical manufacturers, and flow cytometry core facilities worldwide.

Ownership category

akta.pro rank

Product category

Life Sciences Instrumentation

NAICS

Analytical Laboratory Instrument Manufacturing (334516), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)

SIC

Laboratory Analytical Instruments (3826)

akta.pro primary industry

Liquid Handling & Laboratory Automation (Pipettes, Robots, Workstations) (HLAGAIAD)

akta.pro secondary industries

Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics) (HLAHAAAN), General Lab Equipment (Centrifuges, Incubators, Shakers, Ovens) (HLAGAIAC)

Keywords

• Cell counting instruments
• Tissue dissociation systems
• Flow cytometry analyzers
• Single-cell genomics tools
• Cell analysis instruments

Headquarters

HQ city

Ketchum

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Precision Instruments (Capital Equipment): Sale of automated tissue dissociation systems (Singulator) and cell counters (Moxi family). Instruments include Singulator 100, Singulator 200, Singulator 200+, Moxi V, Moxi Z, and Moxi GO II.
2. Disposable Consumables: Cassette-based system uses disposable cassettes for cell counting. Consumables provide recurring revenue stream and zero-maintenance operation model.
3. Professional Services/Application Support: Application scientist consultations for workflow evaluation, offering 20-minute sessions to assess workflow, tissue types, and relevant validation data.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

ORFLO Technologies (doing business as Precision Cell Systems) develops and manufactures precision laboratory instruments for cell-based workflows, primarily automated tissue dissociation systems (Singulator family) and Coulter-principle impedance-based cell counters (Moxi family, including fluorescence-capable Moxi GO II). Products are sold to genomics, translational oncology, cell therapy, pharma, and CRO laboratories, supported by disposable cassettes for recurring consumable revenue.

Product overview

ORFLO Technologies (Precision Cell Systems) offers a suite of precision laboratory instruments for cell-based workflows comprising the Singulator family for automated tissue dissociation and the Moxi family for Coulter-principle cell counting. The Singulator product line includes Singulator 100, Singulator 200, and Singulator 200+ models, providing automated conversion of fresh, frozen, or FFPE tissue to sequencing-ready cells with cold-temperature, software-locked processing. The Moxi product line encompasses Moxi V and Moxi Z (impedance-based Coulter-principle cell counters) and Moxi GO II (combining Coulter-principle counting with two-color fluorescence phenotyping). These instruments are designed as upstream precision solutions feeding sequencers and cytometers in genomics, translational oncology, and regulated manufacturing environments.

Differentiator

Problem solved

Functional benefit

Products and services

• Singulator 100 Entry-level automated tissue dissociation system with software-locked reproducibility for converting fresh, frozen, and FFPE tissue samples to sequencing-ready cells using cold-temperature, enzyme-free processing.
• Singulator 200 Mid-tier automated tissue dissociation system with FFPE-to-nuclei processing without xylene, validated to 2 mg input and operating enzyme-free at 4°C for 6-10 minutes.
• Singulator 200+ High-capacity automated tissue dissociation system with FFPE-to-nuclei processing without xylene, enzyme-free operation at 4°C for 6-10 minutes, software-locked reproducibility across sites, and validated extraction of over 1 million nuclei from a single 50 µm FFPE curl in 40-60 minutes.
• Moxi V Coulter-principle impedance-based cell counter providing NIST-traceable volumetric cell counting and sizing at less than 2% CV, with natural debris exclusion, cassette-based zero-maintenance operation, and results in 8 seconds.
• Moxi Z Coulter-principle impedance-based cell counter with NIST-traceable precision at less than 2% CV, volumetric debris exclusion, cassette-based zero-maintenance operation, and results delivered in 8 seconds.
• Moxi GO II Benchtop cell counter combining Coulter-principle impedance counting with two-color fluorescence (488nm laser and dual PMTs) for viability, GFP, apoptosis, and immunophenotyping assays, with under 10-second processing, zero fluidics, native 21 CFR Part 11 compliance, FCS 3.1 export, and FlowJo compatibility.
• Velocyt Precision instrument for cell-based workflows, listed as a distinct product category in ORFLO's product navigation alongside the Singulator and Moxi families.

Quantifiable outcome

• 10x more viable cells recovered (96% viability) vs. gentleMACS in peer-reviewed glioblastoma study
• +5 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

Feature4 records

Scale indicators8 records

Recent moves4 records

Expansion highlights5 records

Emerging players

• DeNovix: Maker of CellDrop, an image-based cell counter without consumables that competes on convenience rather than impedance-based precision. Targets overlapping academic/research customer base as an alternative to Moxi V/Z.
• Levitas Bio: Emerging single-cell workflow company (LeviCell) in upstream sample prep. Competes with Singulator for tissue-dissociation and rare-cell workflows in translational research.

Direct peers

• Thermo Fisher Scientific: Sells the Countess and Invitrogen line of automated cell counters plus a broad cell therapy/single-cell workflow portfolio. Competes on price-bundling and global reach rather than differentiated precision.
• Miltenyi Biotec: Maker of gentleMACS tissue dissociators — the head-to-head competitor explicitly benchmarked in ORFLO's peer-reviewed glioblastoma study. Overlapping customer base in translational research and cell therapy.
• Beckman Coulter Life Sciences: Established manufacturer of cell counting and sizing instruments (Vi-CELL, Multisizer) based on Coulter principle. Most direct comp on Moxi with broader flow cytometry and life sciences portfolio and vastly larger commercial footprint.
• Chemometec: Specialist in NucleoCounter line of cell counters and the Via1-Casette consumable architecture — directly analogous in cassette-based, precise counting approach to Moxi with strong adoption in cell/gene therapy QC.
• Bio-Rad Laboratories: Producer of the TC20 automated cell counter, a direct competitor to Moxi V/Z in routine lab cell counting. Brings significant brand reach and bundled reagent/flow-cytometry portfolio to academic and biotech customers.

Broad incumbents

• Bio-Techne: Owns ProteinSimple, R&D Systems and ExoDx; competing in single-cell/prep reagents and analytical tools used alongside or instead of ORFLO's workflow in translational and pharma research.
• Sysmex: Hematology and cell counting giant (XE-5000, pocH-100i) whose precision cell-counting capability competes with Moxi in clinical and translational labs. Brings deep installed base and IVD/clinical distribution.
• Sartorius: Bioprocessing and cell-line development platform that touches upstream cell counting and single-cell analysis workflows. Adjacent competitor for cell-therapy and pharma process development customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/precision-cell-systems
• Xx.com/Orflo_Tech

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ORFLO Technologies